Recurrence of primary (AL) amyloidosis in a transplanted heart with four-year survival.
Cardiac amyloidosis has a poor prognosis, with a median survival of approximately 6 months once symptoms develop. This patient had a markedly improved quality of life with cardiac transplantation. We would suggest that with refinement of pretransplant chemotherapy, prolonged survival may be possible in carefully selected cases.
Dubrey
S
S
Division of Cardiology, Boston University School of Medicine, Massachusetts 02118, USA.
Simms
R W
RW
Skinner
M
M
Falk
R H
RH
D000686:Amyloidosis / Q000000981:diagnostic imaging / Q000601:surgery*; D009202:Cardiomyopathies / Q000000981:diagnostic imaging / Q000601:surgery*; D004452:Echocardiography; D005260:Female; D016027:Heart Transplantation; D006801:Humans; D008875:Middle Aged; D012008:Recurrence; D017741:Survivors